Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Medicis invests in Revance; gets option to RT001; terminated

Executive Summary

Medicis has agreed to make a $20mm equity investment (about a 10% stake) in Revance Therapeutics as part of its Series C venture round in exchange for an option to buy Revance or exclusively license North American rights to RT001, its topical botulinum toxin type A in early development.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Equity
    • Product Purchase
    • R&D and Marketing (Licensing)

Related Companies